Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology. (Reumatologi)ORCID iD: 0000-0002-8151-3988
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Center for Molecular Medicine, Stockholm, Sweden.
Show others and affiliations
2025 (English)In: Clinical Immunology, ISSN 1521-6616, E-ISSN 1521-7035, Vol. 275, article id 110476Article in journal (Other academic) Published
Abstract [en]

Patients with rheumatoid arthritis (RA) are at increased risk of diffuse large B cell lymphoma (DLBCL) compared to the general population. Here, we explored the inflammatory profiles in the blood of RA patients who had developed DLBCL. RA-DLBCL patients had significantly higher levels of the pro-inflammatory markers TNF, IL-8, CXCL9, APRIL, and particularly CXCL13 (median 796 vs. 206 pg/mL, p = 0.001), compared to RA controls. By including an extensive autoantibody panel of rheumatoid factor, IgG anti-CCP2, anti-citrullinated protein antibodies (ACPA) fine-specificities, and other anti-modified protein antibodies, all RA-DLBCL patients were autoantibody seropositive. Yet, RA-DLBCL patients did not display significantly different autoantibody signatures compared to RA controls. The levels of immunoglobulin free light chains and C-reactive protein were similar in RA-DLBCL patients and RA controls. In conclusion, RA-DLBCL patients exhibit pro-inflammatory signatures with elevated markers that are important for B cells and may contribute to enhanced B-cell activation and promote lymphoma development.

Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 275, article id 110476
National Category
Rheumatology
Identifiers
URN: urn:nbn:se:uu:diva-550848DOI: 10.1016/j.clim.2025.110476ISI: 001455287700001OAI: oai:DiVA.org:uu-550848DiVA, id: diva2:1938811
Available from: 2025-02-19 Created: 2025-02-19 Last updated: 2025-04-16Bibliographically approved
In thesis
1. Studies on Lymphoma in Rheumatic Diseases and the Pathophysiology of ANCA-Associated Vasculitis
Open this publication in new window or tab >>Studies on Lymphoma in Rheumatic Diseases and the Pathophysiology of ANCA-Associated Vasculitis
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Patients with rheumatic diseases are at increased risk of developing malignant lymphoma, yet the mechanisms linking immune-mediated diseases to lymphomagenesis remain unclear. A deeper understanding of these processes could provide clues to the pathogenesis of both disease categories, improve early risk assessment, and inform preventive strategies. Similarly, the pathophysiological mechanisms of ANCA-associated vasculitis (AAV) and the molecular distinctions underlying the varied clinical outcomes of its subtypes, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), remain poorly understood. Improved insights into these mechanisms could aid in developing more targeted diagnostic tools and treatment strategies.

Paper I investigated B cell-related mechanisms in rheumatoid arthritis (RA)-associated diffuse large B-cell lymphoma (DLBCL). Key findings include elevated levels of several cytokines and chemokines relevant to B-cell biology compared to RA and population controls. In particular, CXCL13 emerged as a protein of interest for its potential role in linking RA to lymphomagenesis.

Paper II examined programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2 in lymphoma tissue from patients with pre-existing rheumatic diseases, with a particular focus on RA-associated DLBCL. A key finding suggests that RA disease severity may influence PD-L1 expression in DLBCL tumor cells.

Paper III characterized lymphomas in patients with pre-existing GPA, focusing on subtypes, localization, and clinical features of both the lymphomas and the underlying rheumatic disease. No clear indications of a predominance of a specific lymphoma subtype were observed, nor was there evidence suggesting local lymphomagenesis in typical GPA target organs.

Paper IV identified key proteins, biological functions, and pathways associated with both shared and distinct disease mechanisms in AAV subtypes, categorized by ANCA serotype into proteinase 3 (PR3)-AAV and myeloperoxidase (MPO)-AAV. The findings highlighted enhanced STAT3 signaling in PR3-AAV and prominent TNF signaling in MPO-AAV, suggesting partially distinct inflammatory processes driving the pathogenesis of these subtypes.

To conclude, the studies in this thesis contribute to the efforts to elucidate the link between autoimmune diseases and lymphoma, as well as the shared and distinct disease mechanisms in AAV.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2025. p. 62
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2125
Keywords
Rheumatoid arthritis, ANCA-associated vasculitis, lymphoma, diffuse large B-cell lymphoma, CXCL13, PD1, PD-ligand, proteomics, STAT3, TNF
National Category
Rheumatology
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-550889 (URN)978-91-513-2392-3 (ISBN)
Public defence
2025-04-11, H:son Holmdahlsalen, Akademiska sjukhuset Ing 100-101, Dag Hammarskjölds väg 8, Uppsala, 09:00 (Swedish)
Opponent
Supervisors
Available from: 2025-03-19 Created: 2025-02-19 Last updated: 2025-03-19

Open Access in DiVA

fulltext(6620 kB)15 downloads
File information
File name FULLTEXT01.pdfFile size 6620 kBChecksum SHA-512
dd4a5d17c648c9a458a0cfe6621252c5e7b54cb1f2a4fa395df2f75d9e1d96bef12fe06422f982cdc5c3f901317f428e591f0c3c89acc6c9006c106a5f2ae051
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Hellbacher, ErikLarsson, AndersEnblad, GunillaBaecklund, Eva
By organisation
RheumatologyClinical ChemistryCancer Immunotherapy
In the same journal
Clinical Immunology
Rheumatology

Search outside of DiVA

GoogleGoogle Scholar
Total: 15 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 59 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf